NCT05084430: Study of Pembrolizumab and M032 (NSC 733972)
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 28 planned
- Started
- 25 Feb 2022
- Primary completion
- 1 Mar 2027
- Arms
- Recurrent MG, Newly Diagnosed MG
- Results
- None posted
- 19 Oct 2021: Trial registered
- 25 Feb 2022: Trial started